Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
Australasian Gastro-Intestinal Trials Group (AGITG)
Other Non-Commercial Sponsor
Australian Government Department of Health, Medical Research Future Fund (MRFF)
Eligible patients will be randomised into one of two groups; both of which will undergo a chemotherapy regimen, containing either a mFOLFIRINOX or Gemcitabine/Nab-paclitaxel drug combination. Only one group will go on to receive stereotactic radiotherapy, before potentially undergoing surgery.